Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease (Q37578490)

21 August 2017

title

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease (English)

1 reference

21 August 2017

1 reference

Makoto Naoi

1

1 reference

21 August 2017

Wakako Maruyama

series ordinal

2

1 reference

21 August 2017

publication date

1 August 2009

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

8

1 reference

21 August 2017

page(s)

1233-1250

1 reference

Parkinson's disease: mechanisms and models

21 August 2017

cites work

1 reference

Molecular pathogenesis of Parkinson disease

21 January 2018

1 reference

Molecular pathogenesis of Parkinson's disease

21 January 2018

1 reference

Diagnosis and treatment of Parkinson disease: molecules to medicine

21 January 2018

1 reference

Genetic clues to the pathogenesis of Parkinson's disease

21 January 2018

1 reference

Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease

21 January 2018

1 reference

Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

21 January 2018

1 reference

Parkinson's disease: genetic versus toxin-induced rodent models

21 January 2018

1 reference

Identification, expression pattern, and characterization of mouse glutaredoxin 2 isoforms.

21 January 2018

1 reference

Apoptosis in Parkinson's disease: signals for neuronal degradation

21 January 2018

1 reference

Death in the substantia nigra: a motor tragedy

21 January 2018

1 reference

Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study

21 January 2018

1 reference

Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.

21 January 2018

1 reference

Expanding insights of mitochondrial dysfunction in Parkinson's disease.

21 January 2018

1 reference

Parkinson's disease: from monogenic forms to genetic susceptibility factors

21 January 2018

1 reference

Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?

21 January 2018

1 reference

Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease

21 January 2018

1 reference

New approaches and therapeutics targeting apoptosis in disease

21 January 2018

1 reference

Pharmacological manipulation of cell death: clinical applications in sight?

21 January 2018

1 reference

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

Stages in the development of Parkinson's disease-related pathology

21 January 2018

1 reference

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

21 January 2018

1 reference

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease

21 January 2018

1 reference

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

Structure and mechanism of monoamine oxidase

21 January 2018

1 reference

Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B

21 January 2018

1 reference

Monoamine oxidases: from tissue homogenates to transgenic mice

21 January 2018

1 reference

Perspectives on MAO-B in aging and neurological disease: where do we go from here?

21 January 2018

1 reference

Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups

21 January 2018

1 reference

Genetics and Parkinson's disease

21 January 2018

1 reference

Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.

21 January 2018

1 reference

Polymorphism in environment responsive genes and association with Parkinson disease

21 January 2018

1 reference

Gene-gene interaction between FGF20 and MAOB in Parkinson disease

21 January 2018

1 reference

Brain monoamine oxidase A activity predicts trait aggression

21 January 2018

1 reference

Association of autism severity with a monoamine oxidase A functional polymorphism.

21 January 2018

1 reference

Clinical applications of MAO-inhibitors

21 January 2018

1 reference

The therapeutic potential of monoamine oxidase inhibitors

21 January 2018

1 reference

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

21 January 2018

1 reference

Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures

21 January 2018

1 reference

Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class

21 January 2018

1 reference

Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors

21 January 2018

1 reference

Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B

21 January 2018

1 reference

Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors

21 January 2018

1 reference

D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity

21 January 2018

1 reference

Selegiline's neuroprotective capacity revisited

21 January 2018

1 reference

Apoptosis and Parkinson's disease

21 January 2018

1 reference

RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.

21 January 2018

1 reference

p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.

21 January 2018

1 reference

Fas-associated factor 1 and Parkinson's disease

21 January 2018

1 reference

Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines

21 January 2018

1 reference

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

21 January 2018

1 reference

Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease

21 January 2018

1 reference

Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease

21 January 2018

1 reference

Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component

21 January 2018

1 reference

A tale of two mitochondrial channels, MAC and PTP, in apoptosis

21 January 2018

1 reference

Mitochondrial membrane permeabilization in cell death

21 January 2018

1 reference

Role of the mitochondrial membrane permeability transition in cell death

21 January 2018

1 reference

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

21 January 2018

1 reference

Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation.

21 January 2018

1 reference

Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer

21 January 2018

1 reference

Pharmacological manipulation of Bcl-2 family members to control cell death

21 January 2018

1 reference

Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications

21 January 2018

1 reference

Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins

21 January 2018

1 reference

Bcl-2 family and the central nervous system: from rheostat to real complex.

21 January 2018

1 reference

RNA interference technologies for understanding and treating neurodegenerative diseases

21 January 2018

1 reference

Therapeutic gene silencing in neurological disorders, using interfering RNA.

21 January 2018

1 reference

RNA knockdown as a potential therapeutic strategy in Parkinson's disease.

21 January 2018

1 reference

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

21 January 2018

1 reference

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells

21 January 2018

1 reference

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

21 January 2018

1 reference

N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.

21 January 2018

1 reference

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

21 January 2018

1 reference

Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

21 January 2018

1 reference

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

21 January 2018

1 reference

Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis

21 January 2018

1 reference

N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor

21 January 2018

1 reference

Effects of R-(-)-BPAP on the expressions of neurotrophins and their receptors in mesencephalic slices

21 January 2018

1 reference

GDNF family receptor complexes are emerging drug targets

21 January 2018

1 reference

Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease

21 January 2018

1 reference

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease

21 January 2018

1 reference

Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?

21 January 2018

1 reference

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal

21 January 2018

1 reference

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

21 January 2018

1 reference

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

21 January 2018

1 reference

Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease

21 January 2018

1 reference

Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain

21 January 2018

1 reference

Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl

21 January 2018

1 reference

Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins

21 January 2018

1 reference

Effects of selegiline on antioxidant systems in the nigrostriatum in rat

21 January 2018

1 reference

Novel functions and signalling pathways for GDNF.

21 January 2018

1 reference

Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways.

21 January 2018

1 reference

Neurotrophin-regulated signalling pathways

21 January 2018

1 reference

Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

21 January 2018

1 reference

NF-kappaB at the crossroads of life and death

21 January 2018

1 reference

NF-kappa B as a therapeutic target in neurodegenerative diseases

21 January 2018

1 reference

A dual role of the NF-kappaB pathway in neonatal hypoxic-ischemic brain damage

21 January 2018

1 reference

Activation of p38 and N-acetylcysteine-sensitive c-Jun NH2-terminal kinase signaling cascades is required for induction of apoptosis in Parkinson's disease cybrids

21 January 2018

1 reference

Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

21 January 2018

1 reference

Bcl-2 attenuation of oxidative cell death is associated with up-regulation of gamma-glutamylcysteine ligase via constitutive NF-kappaB activation

21 January 2018

1 reference

Genetic analysis of NF- B/Rel transcription factors defines functional specificities

21 January 2018

1 reference

Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons

21 January 2018

1 reference

Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling

21 January 2018

1 reference

Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor

21 January 2018

1 reference

Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway

21 January 2018

1 reference

MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology

21 January 2018

1 reference

Biochemical effects of the monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B-deficient mice

21 January 2018

1 reference

Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells

21 January 2018

1 reference

Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice

21 January 2018

1 reference

Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells

21 January 2018

1 reference

Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway

21 January 2018

1 reference

R1, a novel repressor of the human monoamine oxidase A

21 January 2018

1 reference

Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1.

21 January 2018

1 reference

Parkin suppresses the expression of monoamine oxidases

21 January 2018

1 reference

On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited

21 January 2018

1 reference

Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands

21 January 2018

1 reference

Characterisation of imidazoline I2 binding sites in pig brain

21 January 2018

1 reference

Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice

21 January 2018

1 reference

Neuroprotection by pharmacologic blockade of the GAPDH death cascade

21 January 2018

1 reference

Nitric oxide-GAPDH-Siah: a novel cell death cascade

21 January 2018

1 reference

Modulation of [3H]quinpirole binding at striatal D2 dopamine receptors by a monoamine oxidaseA-like site: evidence from radioligand binding studies and D2 receptor- and MAO(A)-deficient mice

21 January 2018

1 reference

Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes

21 January 2018

1 reference

Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture

21 January 2018

1 reference

Evidence in favour of a role for peripheral-type benzodiazepine receptor ligands in amplification of neuronal apoptosis

21 January 2018

1 reference

Biomarkers and Parkinson's disease

21 January 2018

1 reference

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

21 January 2018

1 reference

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease.

21 January 2018

1 reference

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review

21 January 2018

1 reference

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

21 January 2018

1 reference

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease

21 January 2018

1 reference

Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells

21 January 2018

1 reference

Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors.

21 January 2018

1 reference

New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.

21 January 2018

1 reference

Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs

21 January 2018

1 reference

Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling

21 January 2018

1 reference

Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B.

21 January 2018

1 reference

Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B

21 January 2018

1 reference

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

Multifunctional drugs with different CNS targets for neuropsychiatric disorders

21 January 2018

1 reference

Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).

21 January 2018

1 reference

The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats

21 January 2018

1 reference

The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats

21 January 2018

1 reference

Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents

21 January 2018

1 reference

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

21 January 2018

1 reference

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

21 January 2018

1 reference

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

21 January 2018

1 reference

Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

21 January 2018

1 reference

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

21 January 2018

1 reference

Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model

21 January 2018

1 reference

Neuroprotection by rasagiline in thiamine deficient rats

21 January 2018

1 reference

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy

21 January 2018

1 reference

Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells

21 January 2018

1 reference

Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells

21 January 2018

1 reference

TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.

21 January 2018

1 reference

The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity

21 January 2018

1 reference

The effect of low oral doses of (-)-deprenyl and its metabolites on DSP-4 toxicity

21 January 2018

1 reference

Neuroprotective Effect of Deprenyl in Sensory Neurons of Axotomized Dorsal Root Ganglion

21 January 2018

1 reference

Neural progenitor cells are protected against MPTP by MAO-B inhibitors

21 January 2018

1 reference

L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats

21 January 2018

1 reference

1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline

21 January 2018

1 reference

Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells

21 January 2018

1 reference

TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

21 January 2018

1 reference

An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease

21 January 2018

1 reference

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

21 January 2018

1 reference

Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

21 January 2018

1 reference

21 January 2018

1 reference

TAT-mediated endocytotic delivery of the loop deletion Bcl-2 protein protects neurons against cell death

21 January 2018

1 reference

Regulation of Cu/Zn-Superoxide Dismutase Expression via the Phosphatidylinositol 3 Kinase/Akt Pathway and Nuclear Factor- B

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.09.68

1 reference

21 August 2017

1 reference